Jessamy Boyd, MD
Radiation Oncology · Dallas, TXNPI 1497921134
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $473, 2.1 times the $221 reported in 2019.
Across 29 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zap Surgical Systems, Inc.$91
- Johnson & Johnson$77
- AstraZeneca$63
- Bayer$63
- Novartis$56
- Regeneron Healthcare Solutions, Inc.$55
- plus $349 from 12 others
What the payments were for
- Food & beverage$752100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zap Surgical Systems, Inc. | 1 | $91 |
| Johnson & Johnson | 4 | $77 |
| AstraZeneca | 3 | $63 |
| Bayer | 3 | $63 |
| Novartis | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| GT Medical Technologies, Inc | 1 | $45 |
| Merck | 2 | $43 |
| Sobi, Inc | 2 | $43 |
| Tactile Systems Technology Inc | 1 | $33 |
| Syndax Pharmaceuticals, Inc. | 1 | $27 |
| Novocure Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Incyte Corporation | 1 | $25 |
| Fortovia Therapeutics, Inc. | 1 | $23 |
| AbbVie | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$752 in reported general payments places this provider in the 55th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SsdSilver Sulfadiazine | 15 | $217 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Dallas
- Hak ChoyDallas$119K
- Robert TimmermanDallas$77K
- Puneeth IyengarDallas$60K
- Assal RahimiDallas$43K
- Neil DesaiDallas$29K
- Kiran KumarDallas$29K
- Kenneth WestoverDallas$24K
- Jonathan VermaDallas$6K
- James WelshHouston$421K
- Stephen ChunHouston$344K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.